Skip to main content

Table 1 Phenotypic characterization of ADSCs-SVF after isolation and activation with PRP and photobiostimulation in all patients enrolled (n=14) in the study

From: A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis

  Differentiation markers
Patients CD29 CD13 CD73 CD90 CD105 CD116 CD44 CD34 CD31 CD45
1 65.2 41.8 61.6 60.1 49.2 59.1 88.5 21.2 0.8 0.1
2 78.3 50.3 66.8 45.3 53.1 56.2 91.2 25.5 0.5 0.2
3 81.5 47.9 56.3 57.6 47.7 59.2 92.1 31.1 0.3 0
4 79.9 51.8 66.2 61.8 50.6 61.8 90.2 35.6 0 0.1
5 80.4 37.2 55.2 45.7 48.7 49.4 92.7 22.2 0.2 0.5
6 82.2 54.1 78.9 69.8 54.5 63.9 91.4 35.7 1 0
7 81.6 53.3 76.6 68.8 49.9 62.8 88.6 27.9 0.7 0
8 86.7 56.3 68.7 59.9 51.4 62.6 90.1 33.1 0.8 0.2
9 77.4 43.6 57.5 64.1 49.4 62.7 93.2 27.9 1.1 0.1
10 78.8 58.7 66.9 52.8 45.1 62.9 88.9 21.6 08 0.1
11 76.9 60.1 77.9 59.6 48.8 59.6 89.4 26.4 0.9 1
12 78.9 51.9 50.9 59.9 52.2 63.8 90.6 37.1 0.9 0.3
13 80.3 52.8 79.1 61.7 49.8 64.1 89.3 25.4 1 0.2
14 79.7 49.6 75.8 65.5 51.8 63.7 88.8 30.5 0.6 0
Median % (range) 79.1 54.2 67.7 59.3 50.1 60.8 90,3 28.8 0.7 0.2
(65.2 – 86.7) (37.2 – 67.1) (55.2 – 79.1) (45.3 – 69.4) (48.7 – 58.2) (49.4- 64.1) (88.5 – 93.6) (21.2 – 37.1) (0–1.1) (0.2-1)
  1. Abbreviations: ADSCs-SVF Adipose derived stromal cells-stromal vascular fraction.